Immune thrombocytopenia secondary to COVID-19: a systematic review
S Bhattacharjee, M Banerjee - SN comprehensive clinical medicine, 2020 - Springer
Immune thrombocytopenia, often known as immune thrombocytopenic purpura (ITP), has
emerged as an important complication of COVID-19. A systematic review was done to …
emerged as an important complication of COVID-19. A systematic review was done to …
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
U Jäger, W Barcellini, CM Broome, MA Gertz, A Hill… - Blood reviews, 2020 - Elsevier
Autoimmune hemolytic anemias (AIHAs) are rare and heterogeneous disorders
characterized by the destruction of red blood cells through warm or cold antibodies. There is …
characterized by the destruction of red blood cells through warm or cold antibodies. There is …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
JR Brahmer, H Abu-Sbeih, PA Ascierto… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …
cancers. While these immunotherapies have improved patient outcomes in many clinical …
[HTML][HTML] Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia
DJ Kuter, M Efraim, J Mayer, M Trněný… - … England Journal of …, 2022 - Mass Medical Soc
Background Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase,
may increase platelet counts in patients with immune thrombocytopenia by means of dual …
may increase platelet counts in patients with immune thrombocytopenia by means of dual …
American Society of Hematology 2019 guidelines for immune thrombocytopenia
C Neunert, DR Terrell, DM Arnold, G Buchanan… - Blood …, 2019 - ashpublications.org
Background: Despite an increase in the number of therapies available to treat patients with
immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist …
immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist …
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …
practices for the management of patients with immune thrombocytopenia (ITP). This article is …
[HTML][HTML] Mycophenolate mofetil for first-line treatment of immune thrombocytopenia
CA Bradbury, J Pell, Q Hill, C Bagot… - … England Journal of …, 2021 - Mass Medical Soc
Background Immune thrombocytopenia is a rare autoimmune disorder with associated
bleeding risk and fatigue. Recommended first-line treatment for immune thrombocytopenia …
bleeding risk and fatigue. Recommended first-line treatment for immune thrombocytopenia …
Clinical updates in adult immune thrombocytopenia
MP Lambert, TB Gernsheimer - Blood, The Journal of the …, 2017 - ashpublications.org
Immune thrombocytopenia (ITP) occurs in 2 to 4/100 000 adults and results in variable
bleeding symptoms and thrombocytopenia. In the last decade, changes in our …
bleeding symptoms and thrombocytopenia. In the last decade, changes in our …
Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)
Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low
platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated …
platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated …